CHENGDU, China, May 11, 2014 /PRNewswire/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API), today announced that the Company's Annual Meeting of Shareholders for fiscal year ended June 30, 2013 which was scheduled to be held on Wednesday, April 30, 2014 (the "Meeting") has been adjourned. Please note the following updated information pertinent to our upcoming meeting: Issuer Name: Tianyin Pharmaceutical Co., Inc.Type of Meeting: Annual Shareholder MeetingCusip Number: 88630M 10 4Record Date: March 3, 2014Meeting Date: May 28, 2014 (As Adjourned)Meeting Time: 9:30 AM (Eastern Time) Any shareholders as of the Record Date who have not yet submitted their proxies may still do so prior to the adjourned meeting date. For any questions, please contact Rico Portaro at firstname.lastname@example.org, call (702) 818-5898, or fax (702) 974-1444. About TPI Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 10 are included in the essential drug list (EDL) of China. For more information about TPI, please visit: http://www.tianyinpharma.comSafe Harbor Statement The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.